https://www.nasdaq.com/press-release/aeterna-zentaris-to-present-at-the-h.c.-wainwright-bioconnect-conference-2022-01-05
https://www.nasdaq.com/press-release/aeterna-zentaris-appoints-giuliano-la-fratta-as-chief-financial-officer-2021-12-23
https://www.nasdaq.com/press-release/aeterna-zentaris-reports-third-quarter-2021-financial-results-and-provides-pipeline
https://www.nasdaq.com/press-release/aeterna-zentaris-to-present-at-the-h.c.-wainwright-23rd-annual-global-investment
https://www.nasdaq.com/press-release/aeterna-zentaris-reports-second-quarter-2021-financial-results-and-provides-pipeline
https://www.nasdaq.com/press-release/aeterna-zentaris-receives-nasdaq-notification-regarding-minimum-bid-price-0
https://www.nasdaq.com/press-release/aeterna-zentaris-engages-dr.-michael-levy-to-support-development-of-autoimmune-and
https://www.nasdaq.com/press-release/aeterna-zentaris-announces-final-settlement-of-previously-disclosed-class-action
https://www.nasdaq.com/press-release/aeterna-zentaris-announces-the-start-of-preclinical-development-of-macimorelin-at-the
https://www.nasdaq.com/press-release/aeterna-zentaris-commences-pivotal-phase-3-detect-trial-for-the-diagnosis-of
https://www.nasdaq.com/press-release/aeterna-zentaris-to-present-at-the-q2-virtual-investor-summit-2021-05-10
https://www.nasdaq.com/press-release/aeterna-zentaris-announces-the-selection-of-a-development-candidate-in-the-dc-pth
https://www.nasdaq.com/press-release/aeterna-zentaris-announces-results-of-2021-annual-meeting-of-shareholders-2021-05-05
https://www.nasdaq.com/press-release/aeterna-zentaris-reports-first-quarter-2021-financial-results-and-provides-pipeline
https://www.nasdaq.com/press-release/aeterna-zentaris-appoints-michael-teifel-ph.d.-as-senior-vice-president-non-clinical
https://www.nasdaq.com/press-release/aeterna-zentaris-announces-virtual-2021-annual-meeting-of-shareholders-2021-04-28
https://www.nasdaq.com/press-release/aeterna-zentaris-reports-fourth-quarter-and-full-year-2020-financial-results-2021-03
https://www.nasdaq.com/press-release/aeterna-zentaris-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2021-03
https://www.nasdaq.com/press-release/aeterna-zentaris-announces-exclusive-license-agreement-and-research-contract-with
https://www.nasdaq.com/press-release/aeterna-zentaris-continues-to-demonstrate-pipeline-expansion-announces-the-initiation
https://www.nasdaq.com/press-release/aeterna-zentaris-to-present-at-the-h.c.-wainwright-global-life-sciences-conference
https://www.nasdaq.com/press-release/aeterna-zentaris-announces-closing-of-%2429.7-million-bought-deal-offering-of-common
https://www.nasdaq.com/press-release/aeterna-zentaris-increases-previously-announced-bought-deal-offering-of-common-shares
https://www.nasdaq.com/press-release/aeterna-zentaris-announces-%2410.0-million-bought-deal-offering-of-common-shares-2021
https://www.nasdaq.com/press-release/aeterna-zentaris-announces-evaluation-and-potential-development-of-an-oral
https://www.nasdaq.com/press-release/aeterna-zentaris-expands-orphan-drug-development-pipeline-with-targeted
https://www.nasdaq.com/press-release/aeterna-zentaris-granted-180-day-extension-by-nasdaq-to-regain-compliance-with
https://www.nasdaq.com/press-release/aeterna-zentaris-to-present-at-noblecon17-2021-01-15
https://www.nasdaq.com/press-release/aeterna-zentaris-to-present-at-the-h.c.-wainwright-bioconnect-2021-virtual-conference
https://www.nasdaq.com/press-release/aeterna-zentaris-announces-european-licensing-agreement-with-consilient-health-ltd.
https://www.nasdaq.com/press-release/aeterna-zentaris-amends-license-agreement-with-novo-nordisk-for-commercialization-and
https://www.nasdaq.com/press-release/aeterna-zentaris-reports-third-quarter-2020-financial-results-and-provides-business
https://www.nasdaq.com/press-release/aeterna-zentaris-provides-corporate-update-2020-09-16
https://www.nasdaq.com/press-release/aeterna-zentaris-to-present-at-the-h.c.-wainwright-22nd-annual-global-investment
https://www.nasdaq.com/press-release/aeterna-zentaris-announced-presentation-of-positive-results-from-first-pediatric
https://www.nasdaq.com/press-release/aeterna-zentaris-reports-second-quarter-2020-financial-results-and-provides-business
https://www.nasdaq.com/press-release/aeterna-zentaris-announces-closing-of-%247.0-million-registered-direct-offering-priced
https://www.nasdaq.com/press-release/aeterna-zentaris-announces-%247.0-million-registered-direct-offering-priced-at-the
https://www.nasdaq.com/press-release/aeterna-zentaris-announces-continued-expansion-of-intellectual-property-portfolio-for
https://www.nasdaq.com/press-release/aeterna-zentaris-announces-abstract-of-results-from-first-pediatric-study-of
https://www.nasdaq.com/press-release/aeterna-zentaris-receives-nasdaq-notification-regarding-minimum-bid-price-compliance
https://www.nasdaq.com/press-release/aeterna-zentaris-announces-closing-of-%2412-million-public-offering-2020-07-07
https://www.nasdaq.com/press-release/aeterna-zentaris-announces-pricing-of-%2412-million-public-offering-2020-07-01
https://www.nasdaq.com/press-release/aeterna-zentaris-announces-strategic-review-and-engagement-financial-advisor-2019-04
